Byetta Pancreatitis & Death Lawsuit

Send to Friend | Bookmark | Live Chat

Byetta, a drug used to treat adults with type 2 diabetes has been linked to serious, life-threatening side effects including acute hemorrhagic and/or necrotizing pancreatitis.

IMPORTANT: There are no signs or symptoms that distinguish acute hemorrhagic or necrotizing pancreatitis associated with Byetta from the less severe form of pancreatitis.

If you or a loved one have developed pancreatitis while taking Byetta, you should contact us immediately. You may be entitled to compensation for your injuries and we can help.

Breaking News - First Byetta Lawsuit Filed

AMYLIN PHARMACEUTICALS DIABETES DRUG BYETTA® THE FOCUS OF CALIFORNIA LAWSUIT - (8/19/08) A Virginia man yesterday filed what is believed to be the first personal injury lawsuit stemming from injuries associated with the use of Byetta®, an injectable medication for diabetes.

Urgent FDA Byetta Pancreatitis Update

As of 8/18/2008, the FDA has reviewed 30 postmarketing reports of acute pancreatitis in patients taking Byetta. Of the most recent 6 cases of hemorrhagic or necrotizing pancreatitis, all patients required hospitalization, two patients died and four patients were recovering at time of reporting.

What’s the Problem?

The U.S. Food & Drug Administration (FDA) has issued two Healthcare Alerts (10/2007 & 08/2008) linking approximately 30 cases of acute pancreatitis in patients taking Byetta.

Recently, the FDA has told healthcare professionals to advise patients taking Byetta to seek emergency medical services if they begin to experience unexplained persistent severe abdominal pain which may or may not be accompanied by vomiting. This could be a sign of acute pancreatitis.

In addition, the FDA has recently requested that the manufacturer of Byetta, Amylin Pharmaceuticals, Inc. to add stronger and more prominent warnings in the product label about the risk of acute hemorrhagic or necrotizing pancreatitis.

Byetta Overview - Signs & Symptoms of Acute Pancreatitis

Byetta is a medicine given by injection to help treat adults with type 2 diabetes.  Commonly reported side effects of Byetta include nausea, vomiting, diarrhea, indigestion and upper abdominal discomfort.  However, the presence of unexplained, severe abdominal pain, with or without nausea and vomiting, raises the suspicion of acute pancreatitis, a potentially serious condition that requires prompt medical attention. Therefore, patients taking Byetta should promptly seek medical care if they experience unexplained severe abdominal pain with or without nausea and vomiting.

Do I Have a Byetta Lawsuit?

The Defective Drug & Products Liability Litigation Groups at our law firm are an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in defective drug lawsuits. We are pursuing individual litigation nationwide and currently accepting new Byetta side effects and pancreatitis cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field

Byetta News (National)

LegalView Updates Brain Injury Site with Information on TBI Disabled ... - PR.com LegalView recently updated its traumatic brain injury (TBI) blog to include information on the story of one soldier?s family who have taken on the role of caregivers. Physicians believe that the signature wound of soldiers returning from Iraq is a ... LegalView Updates Avandia Information Portal with News That Avandia ... - PR.com LegalView recently relaunched is Avandia information portal with updated news that the type 2 diabetes drug has more safety risks than drugs of a similar nature. A study from U.S. researchers was published evaluating the dangers of the diabetes drugs ... Insulin giant Novo Nordisk has strong cash flow, little debt - Orlando Sentinel Answer: The world's largest maker of insulin holds more than half of the global market in diabetes treatments. Not only is the number of diabetes cases expected to rise because of an aging population and sedentary lifestyles, but the chronic disease ... Amylin's Byetta Battle - CNBC Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals. The stock has been on a slide since the FDA and the company disclosed a total ... Amylin shares fall on 3Q report, Byetta concerns - Forbes Shares of Amylin Pharmaceuticals Inc. dropped to their lowest point in more than six years Wednesday, following a weak third-quarter profit report, reduced revenue guidance and concerns that its next-generation Byetta may take longer than expected to ... 4 More Deaths Reported Among Byetta Patients - Atlanta Journal Constitution TUESDAY, Aug. 26 (HealthDay News) -- The makers of the type 2 diabetes drug Byetta reported Tuesday the deaths of four more people who'd been taking the medication. The announcement by Eli Lilly and Amylin Pharmaceuticals Inc. came a week after the U ... Amylin's Once A Week Byetta: Good Is Not Enough - CNBC This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year ... Amylin Sinks as U.S. Eyes New Study for Weekly Byetta (Update2) - Bloomberg Nov. 4 (Bloomberg) -- Amylin Pharmaceuticals Inc. fell the most in more than nine years in Nasdaq trading after the company said data for the once-weekly version of the diabetes drug Byetta didn't satisfy U.S. health regulators' standards. Data from ... Amylin Builds on the Success of Byetta - Genetic Engineering News Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The increasing incidence of obesity has ushered in a ripe market for type 2 diabetes drugs. The commercial landscape is dominated by ... Sector Snap: Diabetes treatment guidelines change - Forbes New medical industry treatment guidelines could give Eli Lilly & Co.'s and Amylin Pharmaceuticals Inc.'s diabetes drug Byetta a boost as it continues to deal with safety concerns on the market and lackluster sales. On Wednesday, the American Diabetes ...